- Business
- ExaWizards Inc. (4259.T) develops and provides AI-enabled services and products for industrial innovation, digital transformation, and social issue solutions primarily in Japan. The company operates through its core exaBase platform, which offers a suite of generative AI and multi-agent AI products including exaBase Generative AI for general enterprise use; exaBase Automate for Anyone for robotic process automation; exaBase Empower for HR data analysis, recruitment, and talent allocation; exaBase Role Playing and Sales Agent for sales training and knowledge management; exaBase DX Assessment & Learning for digital skills evaluation; exaBase Studio for custom AI development; exaBase IR Assistant for investor relations; exaBase FAQ for customer support; and exaBase Generative AI for Municipalities for public sector efficiency. Additionally, its CareWiz series delivers AI-powered caregiving solutions such as CareWiz Toruto and Tayoruto to support super-aged societies by enhancing caregiver productivity and personal interaction; the company also provides consulting services for AI planning, design, development, and operations. Founded in February 2016 and headquartered at 5F Sumitomo Fudosan Mita First Building, 4-2-8 Shibaura, Minato-ku, Tokyo, ExaWizards maintains offices in Hamamatsu, Osaka, and Fukuoka, with subsidiaries including ExaMD Inc. for medical AI devices, Exa Enterprise AI Inc., Exa HomeCare Inc., STADIUM Co., Ltd., and Xware Corporation targeting sectors like healthcare, finance, manufacturing, and government. Recent developments include the September 2025 launch of exaBase Empower with a six-month free trial for HR transformation; the beta release of exaBase Automate for Anyone in September 2025 with over 100 pre-registrations; adoption of exaBase Role Playing by Shoko Chukin Bank in September 2025 and exaBase IR Assistant by Nikon in June 2025; ExaMD's partnerships with EPS Group in July and June 2025 to establish a Software as a Medical Device (SaMD) value chain for products like LocoStep gait analysis app and dementia diagnosis tools, the latter published in PLOS ONE and designated for priority review; ExaMD obtaining Type II Medical Device licenses in April 2025; and a new leadership structure announced in June 2025 under President Makoto Haruta.